223 related articles for article (PubMed ID: 31189116)
61. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
62. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
Kalemkerian GP; Ou X
Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
[TBL] [Abstract][Full Text] [Related]
63. Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer.
Han M; Dai J; Zhang Y; Lin Q; Jiang M; Xu X; Liu Q; Jia J
Oncol Rep; 2012 Dec; 28(6):2233-8. PubMed ID: 22992788
[TBL] [Abstract][Full Text] [Related]
64. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
65. Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
Ito T; Matsubara D; Tanaka I; Makiya K; Tanei ZI; Kumagai Y; Shiu SJ; Nakaoka HJ; Ishikawa S; Isagawa T; Morikawa T; Shinozaki-Ushiku A; Goto Y; Nakano T; Tsuchiya T; Tsubochi H; Komura D; Aburatani H; Dobashi Y; Nakajima J; Endo S; Fukayama M; Sekido Y; Niki T; Murakami Y
Cancer Sci; 2016 Oct; 107(10):1527-1538. PubMed ID: 27418196
[TBL] [Abstract][Full Text] [Related]
66. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
[TBL] [Abstract][Full Text] [Related]
67. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
68. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
[TBL] [Abstract][Full Text] [Related]
69. Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel.
Locke VL; Davey RA; Davey MW
Anticancer Drugs; 2003 Aug; 14(7):523-31. PubMed ID: 12960736
[TBL] [Abstract][Full Text] [Related]
70. The role of cisplatin in the treatment of small-cell lung cancer?
Berghmans T; Paesmans M; Sculier JP
Ann Oncol; 2001 May; 12(5):585-6. PubMed ID: 11432613
[No Abstract] [Full Text] [Related]
71. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
72. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
73. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Saijo N; Horiike A
Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
[TBL] [Abstract][Full Text] [Related]
74. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
75. Topotecan: a review of its efficacy in small cell lung cancer.
Ormrod D; Spencer CM
Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
[TBL] [Abstract][Full Text] [Related]
76. Chemotherapy as treatment of primary and recurrent small cell lung cancer.
Schuette W
Lung Cancer; 2001 Sep; 33 Suppl 1():S99-107. PubMed ID: 11576714
[TBL] [Abstract][Full Text] [Related]
77. Cisplatin and Vinorelbine -Mediated Electrochemotherapeutic Approach Against Multidrug Resistant Small Cell Lung Cancer (H69AR)
Drąg-Zalesińska M; Saczko J; Choromańska A; Szewczyk A; Rembiałkowska N; Kulbacka J; Rzechonek A
Anticancer Res; 2019 Jul; 39(7):3711-3718. PubMed ID: 31262897
[TBL] [Abstract][Full Text] [Related]
78. Current standards of care in small-cell and non-small-cell lung cancer.
Schiller JH
Oncology; 2001; 61 Suppl 1():3-13. PubMed ID: 11598409
[TBL] [Abstract][Full Text] [Related]
79. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
80. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
